Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.44)
# 360
Out of 5,022 analysts
241
Total ratings
44.34%
Success rate
31.08%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $49.12 | +28.27% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $58.96 | +35.69% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $31.69 | +231.33% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $66.11 | +78.49% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $95.29 | -22.34% | 2 | Aug 27, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $27.38 | +16.87% | 8 | Aug 6, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.96 | +84.56% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $10.49 | +176.45% | 3 | Jul 10, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $6.23 | +156.82% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $8.69 | +15.07% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $6.70 | +347.76% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $21.43 | +277.97% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.16 | +35.79% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $63.58 | +93.46% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $2.97 | +2,930.30% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.96 | +257.14% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $73.00 | +80.82% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.95 | +67.22% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $26.46 | +153.21% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $8.04 | +161.19% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $14.79 | +96.08% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.88 | +147.09% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.70 | +196.30% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.52 | +336.51% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.35 | +236.45% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.52 | +821.05% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.79 | +626.26% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.56 | +1,246.15% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.79 | +235.20% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.44 | +1,288.89% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.97 | +479.35% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.65 | +54,445.45% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $11.35 | +3,424.23% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.80 | +10,522.34% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.72 | +2,578.57% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.45 | +5,117.39% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.63 | +574.85% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.06 | +5,560.38% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.30 | +6,823.08% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.44 | +174,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.63 | +25,296.83% | 1 | Jan 9, 2020 |
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.12
Upside: +28.27%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $58.96
Upside: +35.69%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $31.69
Upside: +231.33%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $66.11
Upside: +78.49%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $95.29
Upside: -22.34%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $27.38
Upside: +16.87%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.96
Upside: +84.56%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $10.49
Upside: +176.45%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.23
Upside: +156.82%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $8.69
Upside: +15.07%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.70
Upside: +347.76%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $21.43
Upside: +277.97%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $5.16
Upside: +35.79%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $63.58
Upside: +93.46%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $2.97
Upside: +2,930.30%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.96
Upside: +257.14%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $73.00
Upside: +80.82%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.95
Upside: +67.22%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $26.46
Upside: +153.21%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $8.04
Upside: +161.19%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $14.79
Upside: +96.08%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.88
Upside: +147.09%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.70
Upside: +196.30%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.52
Upside: +336.51%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.35
Upside: +236.45%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.52
Upside: +821.05%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.79
Upside: +626.26%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.56
Upside: +1,246.15%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.79
Upside: +235.20%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.44
Upside: +1,288.89%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.97
Upside: +479.35%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.65
Upside: +54,445.45%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $11.35
Upside: +3,424.23%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.80
Upside: +10,522.34%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.72
Upside: +2,578.57%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $3.45
Upside: +5,117.39%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.63
Upside: +574.85%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.06
Upside: +5,560.38%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.30
Upside: +6,823.08%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.44
Upside: +174,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.63
Upside: +25,296.83%